Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402784 | 0.81 | HSD11B1 (0.53) | MAPTMEN1ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL241413 | 0.80 | MAPT (0.50) | MAPTMEN1ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL3747771 | 0.80 | MAPT (0.49) | MAPTMEN1ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL240570 | 0.79 | MAPT (0.51) | MAPTMEN1ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL240721 | 0.76 | OPRK1 (0.39) | MAPTMEN1ALDH1A1KMT2APARP10 | |
| SCHEMBL5946765 | 0.72 | HSD11B1 (0.59) | HSD11B1HSD17B1POLBCNR2TDP1 | |
| SCHEMBL5946691 | 0.72 | HSD11B1 (0.59) | HSD11B1HSD17B1POLBCNR2TDP1 | |
| SCHEMBL3265557 | 0.72 | EPHX2 (0.49) | MAPTMEN1ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL5946774 | 0.71 | HSD11B1 (0.62) | HSD11B1HSD17B1POLBCNR2TDP1 | |
| SCHEMBL11019763 | 0.70 | HSD11B1 (0.67) | HSD11B1HSD17B1POLBKDM4ECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | MAPT 3783/4885MEN1 1273/4885ALDH1A1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.